Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $98.72 USD
Change Today +0.73 / 0.74%
Volume 75.8K
As of 2:46 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

951 Calle Amanecer

San Clemente, CA 92673

United States

Phone: 949-366-2183

Fax: 949-366-8368

ICU Medical, Inc. engages in the development, manufacture, and sale of medical devices used in infusion therapy, oncology and critical care applications. The company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems, and hemodynamic monitoring systems. The company’s products are used in acute care hospitals and ambulatory clinics in approximately 60 countries worldwide. The company categorizes its products into three major market segments: Infusion Therapy, Critical Care, and Oncology. Products Infusion Therapy Infusion therapy lines, used in hospitals and ambulatory clinics, consist of a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient’s vein. The tube has various injection ports or Y-sites (conventionally, entry tubes covered by rubber caps) to which a secondary infusion line could be connected to permit constant intravenous administration of medications, fluids and nutrients, and to allow instantaneous intravenous administration of medication. Clave Needlefree Technology Prior to the introduction of needle-safe connectors, a conventional infusion line terminated with a male luer connector to which a hollow-bore needle would be attached to penetrate a latex or non-latex rubber covered injection port to make a primary or secondary connection. With the Clave technology, instead of attaching a hollow-bore needle to the male luer, a needlefree connector with Clave technology is used in place of the injection port, and the male luer, without a needle, is threaded into the Clave with a half turn. All types of medications could be administered through the Clave by using a standard syringe or various types of administration sets. The Clave could be used with any conventional peripheral or central vascular access device, both for venous and arterial applications. The resilience of the silicone compression seal permits repeated connections and disconnections without replacing the Clave. The Clave contains no natural rubber latex. The MicroClave is smaller than the standard Clave but is functionally similar. The MicroClave has a feature where upon disconnection of an infusion set or syringe, there is a neutral displacement of fluid. This allows clinicians to utilize known protocols without the risk of device failure and a saline flush regimen, which reduces cost and exposure to the drug heparin. The MicroClave is intended for use on all peripheral and central catheters, which allow it to be used throughout the hospital and reduce line items that the hospital might need to carry and the educational burden of having multiple devices. The MicroClave Clear is functionally identical to the MicroClave, and has a clear housing so that clinicians could visualize the fluid path. The NanoClave is smaller than the MicroClave and is designed for use in customized applications generally found in neonatal and pediatric patient populations. The device also has a clear housing and incorporates Clave technology into a smaller connector, allowing clinicians to flush the connector clear of medications and blood with minimal flush volumes. Neutron The Neutron catheter patency device also features Clave technology, but includes a bi-directional silicone bellows that helps prevent blood reflux into a catheter to minimize the incidence of occlusion, or blocking of the catheter due to a blood clot. The Neutron is primarily designed to be used on patients receiving longer indwelling central venous catheters. Tego The Tego is a needlefree hemodialysis connector that creates a mechanically and microbiologically closed system when attached to the hub of a catheter, eliminating open catheter hubs and lowering the chance of bacterial contamination and infection. Custom Infusion Sets The company has developed software systems and manufacturing processes known as SetMaker and iFactory that permit the company to design a custom infusion set to a hospital’s or

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICUI:US $98.72 USD +0.73

ICUI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.44 USD -0.1878
Cyberonics Inc $60.33 USD -0.175
NxStage Medical Inc $13.76 USD -0.02
Orthofix International NV $33.72 USD +0.49
Wright Medical Group Inc $26.02 USD -0.06
View Industry Companies
 

Industry Analysis

ICUI

Industry Average

Valuation ICUI Industry Range
Price/Earnings 52.8x
Price/Sales 4.9x
Price/Book 3.0x
Price/Cash Flow 52.5x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICU MEDICAL INC, please visit www.icumed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.